# The Non-Coding RNA Journal Club: Highlights on Recent Papers—14 **Authors:** El Cheima Mhamedi, Florent Hubé, Suresh K. Alahari, Francisco J. Enguita, Barbara Pardini, Mark W. Feinberg, Laura Poliseno, Beshoy Armanios, Jing Jin, Xiao-Bo Zhong, Nikolaos Sideris, Salih Bayraktar, Leandro Castellano, Gaetano Santulli, Stanislovas S. Jankauskas, Will S. Plewa, Simon J. Conn, Ling Yang, Patrick K. T. Shiu, Abhishek Kaushik, Alexander Serganov, Massimo Gentile, Giuseppe Viglietto, Nicola Amodio, Tijana Mitić, Andrea Caporali PMC · DOI: 10.3390/ncrna11060075 · Non-Coding RNA · 2025-10-31 ## Full-text entities - **Genes:** Mir17 (microRNA 17) [NCBI Gene 723905] {aka Mirn17, mir-17, mmu-mir-17}, BCL2L11 (BCL2 like 11) [NCBI Gene 10018] {aka BAM, BIM, BOD}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, Ptk7 (PTK7 protein tyrosine kinase 7) [NCBI Gene 71461] {aka 8430404F20Rik, chz, mPTK7/CCK4}, Mir503 (microRNA 503) [NCBI Gene 723879] {aka Mirn503, mmu-mir-503}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Sox6 (SRY (sex determining region Y)-box 6) [NCBI Gene 20679] {aka SOX-LZ}, MIR205 (microRNA 205) [NCBI Gene 406988] {aka MIRN205, mir-205}, Pabpc1 (poly(A) binding protein, cytoplasmic 1) [NCBI Gene 18458] {aka PABP, Pabp1, PabpI, Pabpl1, ePAB}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, LINC00629 (long intergenic non-protein coding RNA 629) [NCBI Gene 100506757] {aka LINC00629A, LINC00629B, LINC00629C, LINC00629D}, Mir20a (microRNA 20a) [NCBI Gene 387139] {aka Mir-20, Mirn20, Mirn20a, mir-20a, mmu-mir-20a}, Tnfsf12 (tumor necrosis factor (ligand) superfamily, member 12) [NCBI Gene 21944] {aka Apo3l, Dr3l, Dr3lg, Tweak}, Lmr1 (leishmaniasis resistance 1) [NCBI Gene 110059], Mir221 (microRNA 221) [NCBI Gene 723827] {aka Mirn221, mir-221, mmu-mir-221}, ALAS1 (5'-aminolevulinate synthase 1) [NCBI Gene 211] {aka ALAS, ALAS-H, ALAS3, ALASH, MIG4}, AGO2 (argonaute RISC catalytic component 2) [NCBI Gene 27161] {aka CASC7, EIF2C2, LESKRES, LINC00980, PPD, Q10}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Alas1 (aminolevulinic acid synthase 1) [NCBI Gene 11655] {aka ALAS, ALAS-N, Alas-1, Alas-h}, Mir16-1 (microRNA 16-1) [NCBI Gene 387134] {aka Mirn16, Mirn16-1, miR-16, mir-16-1}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, SNHG6 (small nucleolar RNA host gene 6) [NCBI Gene 641638] {aka HBII-276HG, NCRNA00058, U87HG}, NONO (non-POU domain containing octamer binding) [NCBI Gene 4841] {aka MRXS34, NMT55, NRB54, P54, P54NRB, PPP1R114}, MED1 (mediator complex subunit 1) [NCBI Gene 5469] {aka CRSP1, CRSP200, DRIP205, DRIP230, PBP, PPARBP}, MIR181A1HG (MIR181A1 host gene) [NCBI Gene 100131234], ITGA2 (integrin subunit alpha 2) [NCBI Gene 3673] {aka BR, CD49B, FMAIT3, GPIa, HPA-5, VLA-2}, Mir106a (microRNA 106a) [NCBI Gene 723829] {aka Mirn106a, mir-106a} - **Diseases:** vascular diseases (MESH:D014652), CAD (MESH:D003324), pulmonary artery hypertension (MESH:D000081029), CLI (MESH:D000089802), mitochondrial myopathy (MESH:D017240), necrosis (MESH:D009336), vascular inflammation (MESH:D007249), tumorigenesis (MESH:D063646), LUAD (MESH:D000077192), hepatic steatosis (MESH:D005234), diabetic vascular disease (MESH:D003925), atherosclerosis (MESH:D050197), restenosis (MESH:D023903), diabetes (MESH:D003920), liver diseases (MESH:D008107), injury to (MESH:D014947), cardiovascular disease (MESH:D002318), hindlimb ischemia (MESH:D007511), cancer (MESH:D009369), hypoxic (MESH:D002534), lung cancer (MESH:D008175), type 2 diabetes (MESH:D003924), toxicity (MESH:D064420), Pancreatic Cancer (MESH:D010190), IPF (MESH:D054990), ischemic (MESH:D002545), ventricular malformation (MESH:D014693), acute hepatic porphyrias (MESH:C562618), NSCLC (MESH:D002289), squamous cell carcinoma (MESH:D002294), MM (MESH:D009101), vascular dysfunction (MESH:D002561), neointimal hyperplasia (MESH:D006965), MAFLD (MESH:C536351) - **Chemicals:** oligonucleotides (MESH:D009841), heme (MESH:D006418), givosiran (MESH:C000630124), cycloheximide (MESH:D003513), MMAE (MESH:C495575), Aptamer (-), lipid (MESH:D008055), amino acid (MESH:D000596) - **Species:** Fusobacterium (genus) [taxon 848], Homo sapiens (human, species) [taxon 9606], Salmonella enterica subsp. enterica serovar Typhimurium (no rank) [taxon 90371], Mus musculus (house mouse, species) [taxon 10090] ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12641628/full.md ## References 34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12641628/full.md --- Source: https://tomesphere.com/paper/PMC12641628